The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 708,991 | 1,239,499 |
| Amortization of right-of-use asset | 14,354 | 27,312 |
| Allowances for expected credit losses | 175,818 | 40,124 |
| Recoveries for expected credit losses | 0 | 94,912 |
| Litigation settlement, loss | - | 0 |
| Depreciation of property, plant and equipment | 29,001 | 54,442 |
| Dividend income | 4,192 | 17,560 |
| Fair value loss/(gain) on investments in equity securities, net | 0 | -91,243 |
| Loss arising from settlement of supplier contract dispute | 0 | - |
| Gain on disposal of investments in equity securities | 27,547 | - |
| Loss on lease termination | 0 | - |
| Operating loss before working capital changes | -521,557 | -1,138,850 |
| Inventories | -208,175 | -173,001 |
| Trade and other receivables | -206,475 | 368,335 |
| Trade and other payables | -1,114,895 | -112,559 |
| Advance payment from customer | -84 | -84,531 |
| Operating lease liabilities | -13,410 | -13,401 |
| Tax (liabilities)/recoverable | 2,169 | 17,304 |
| Net cash used in operating activities | -1,237,465 | -1,561,979 |
| Acquisition of investments in equity securities | 9,064 | - |
| Dividend income | 4,192 | 17,560 |
| Change in fixed deposits placed with original maturities more than three months | 15,872 | 31,227 |
| Purchase of plant and equipment | 5,483 | 30,511 |
| Proceeds from disposal of investments in equity securities | 1,020,873 | - |
| Proceeds from settlement of supplier contract dispute | 0 | - |
| Net cash generated from/(used in) investing activities | 994,646 | -44,178 |
| Advances from directors | 34,187 | -1,385 |
| Share-base compensation | 0 | - |
| Cash paid for fractional shares in reverse stock split | 0 | 505 |
| Net cash generated from financing activities | 34,187 | -1,890 |
| Foreign currency translation adjustment | 28,535 | 258,270 |
| Net change in cash and cash equivalents | -180,097 | -1,349,777 |
| Cash and cash equivalents at beginning of period | 2,886,966 | - |
| Cash and cash equivalents at end of period | 1,357,092 | - |
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)